Obstructive Sleep ApneaNCT03716648
Titration of Oral Appliance Therapy: a Prospective, Randomized Cross-over Trial.
A study testing DISE-assisted titration, PSG-guided titration and subjective titration in people with Obstructive Sleep Apnea, run by University Hospital, Antwerp at 1 site in Belgium.
Trial summary
In this prospective randomized cross-over trial, 3 different titration procedures will be compared: 1. titration of the mandibular advancement device (MAD) in the home setting based on both the physical limits of the patient's mandibular protrusion and the resolution of subjective complaints, as currently often used… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obstructive Sleep Apnea
- What is being tested?
- DISE-assisted titration, PSG-guided titration and subjective titration
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 1 siteBelgium
- Study dates
- 22 May 2019to 7 Apr 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with moderate to severe obstructive sleep apnea (OSA) (obstructive AHI (oAHI) ≥ 15/h)
- BMI < 30 kg/m²
- Age > 18 year
- PSG < 2 years old with stable body weight (+/- 5 kg), no ENT surgery since most recent PSG and stable clinical condition
- Normal clinical and radiological (incl. OPG), periodontal en temporomandibular joint examination
- Subject is capable of giving informed consent
- No documented abuses (alcohol, drugs, …)
Who cannot join
- Edentulous patients
- Insufficient teeth to support the mandibular advancement device
- Active periodontal problems including tooth mobility
- Active temporomandibular joint dysfunction
- Limited maximum protrusive capacity (<6 mm)
- Limited vertical opening (<25 mm)
Show all 9Show fewer
- Enlarged palatine tonsils (Grade IV tonsils)
- Degenerative neuromuscular disorders
- Pregnancy or willing to become pregnant
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Determination of the Optimal Mandibular Position During Oral Appliance Therapy With a Mandibular Advancement Device in Patients Diagnosed With Obstructive Sleep Apnea.
In this prospective randomized cross-over trial, 3 different titration procedures will be compared:
- titration of the mandibular advancement device (MAD) in the home setting based on both the physical limits of the patient's mandibular protrusion and the resolution of subjective complaints, as currently often used in routine clinical practice;
- an overnight titration PSG using the remotely controlled mandibular positioner (RCMP) with stepwise mandibular protrusion until respiratory events are reduced and
- incremental protrusion of the mandible during DISE using the RCMP until upper airway collapse at all collapsible levels is eliminated.
The aim of this study is to prospectively compare the target protrusion, as well as the treatment outcome in terms of treatment efficacy, of the 3 different titration protocols.
Read the detailed description
After inclusion, each patient will undergo three different titration procedures of the protrusive mandibular position or target protrusion for the MAD treatment, in a randomized order: subjective titration, titration during DISE, titration during PSG.
- Subjective titration: After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
- Titration during drug-induced sleep endoscopy (DISE) - DISE-assisted titration: The DISE will be performed by an ear-nose-throat (ENT)surgeon experienced in DISE in order to visualize the dose-dependent effect of the mandibular protrusion on the upper airway collapsibility. The DISE is performed in a semi-dark and silent operating theatre with the patient lying in supine position. The different collapsible levels of the upper airway that can be investigated during DISE are the palate (velopharynx), the oropharynx, the tongue base, the hypopharynx and the epiglottis. The degree of collapse at each level is reported as none, partial or complete. The pattern of the pharyngeal collapse during the obstructive events are classified as concentric, anteroposterior and/or laterolateral. Upon connection of the RCMP to a dedicated laptop, calibration of the actual versus the software-guided protrusion is verified using the RCMP ruler and proprietary developed software, to rule out day-to-day variation caused by environmental factors such as room temperature or humidity. This procedure ensures the mandibular displacement to be read out correctly from the ruler present at the upper tray fitted over the tooth arcs. After the calibration, the RCMP-trays are fitted in edge-to-edge position to avoid excessive muscle tension. A flexible fibreoptic nasendoscope will be introduced by the ENT surgeon in the awake patient to evaluate the awake upper airway state. Thereafter, sedation will be induced by intravenous administration of midazolam (bolus injection of 1.0 to 2.0 mg) and propofol using a target-controlled infusion system (2.0 to 3.0 μg/mL). The transition to unconsciousness similar to stage 2 sleep is aimed at and examined by assuring absence of patients' eyelash reflex after stimulation by means of a gentle brush. Findings are noted using a uniform upper airway scoring system evaluating level of snoring, presence of apneas and degree of oxygen saturation, degree and configuration of obstruction(s) and the level of upper airway collapse. When target sedation is reached, examined by assuring absence of patients' eyelash reflex after stimulation by means of a gentle brush, the RCMP will be remotely protruded in increments of 2 mm in response to the visualized upper airway collapse at the different collapsible levels until a stable upper airway together with absence of desaturations and snoring is reached. If a stable upper airway in absence of snoring is noted, oxygen desaturation and apneas are evaluated, and the mandible will be remotely retruded for 1 mm. If the upper airway remains stable, further so-called 'reversed titration' will continue. This approach will be repeated until the effective target protrusive position can be determined, defined as the minimal mandibular threshold position corresponding to a stable upper airway in the absence of snoring, oxygen desaturation and apneas. When a stable upper airway is reached, the titration procedure will be continued in 0.5 mm steps, to be as precise as possible. After every protrusive or retrusive movement the RCMP protrusion will be checked on the RCMP ruler versus the protrusion measured by the software, assuring correct positioning of the mandible during the upper airway evaluation.
- Titration during polysomnography (PSG):
At the start of the PSG, the participant's dental trays are attached to the mandibular positioner of the RCMP device, and the positioner is calibrated to the PSG system using the device software. The titration procedure that will be used in this study is previously described. Once asleep, the patient's mandible will be protruded remotely in 0.5 mm steps in response to evidence of apneas and/or hypopneas. If an EEG arousal occurs, no further advancement will be attempted until stable sleep resumes. Stepwise mandibular protrusion will continue until respiratory events are reduced to normal in all sleep stages, and in both supine and lateral position, or until maximal protrusion is reached. Afterwards, an independent researcher will score the PSG together with body position and mandibular position signals and will predict success or failure with MAD therapy based on the predetermined interpretative rules. The patient needs to have rapid eye movement (REM) sleep for ≥ 5 minutes in the supine position or in the lateral position, if REM in supine position was not observed. All REM cycles will be evaluated to identify a minimum 5 minutes' interval where ≤ 1 respiratory event occurred. If this is the case, the PSG will be scored as predicted MAD success for that protrusive position. If not, the PSG will be judged to predict therapeutic failure. The predicted effective target protrusive position is the minimum protrusive position that is associated with ≤ 1 respiratory event per 5-minutes REM interval. If the PSG is scored as predicted success, the predicted effective target protrusive position is provided to the dentist to start MAD therapy in that position. If the PSG is scored as predicted failure, an alternative position equal to 75% of maximal protrusion is provided.
A polygraphic evaluation of the MAD efficacy will be planned after each titration procedure. Furthermore, the patients will be asked to fill out questionnaires regarding snoring, daytime sleepiness (Epworth Sleepiness Scale, ESS), fatigue (Checklist Individual Strength, CIS20R) and side effects of the MAD treatment.
A wash-out period of one week is inserted between the polygraphic evaluation of the protrusive position obtained during a titration procedure and the start of the next titration procedure.
- Conditions
- Obstructive Sleep Apnea
- Being tested
- DISE-assisted titration, PSG-guided titration, subjective titration
- Medical subject headings
- Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DISE-assisted titrationDiagnostic test
Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
PSG-guided titrationDiagnostic test
Titration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy.
subjective titrationDevice
Titration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness.
| Study group | Role | What they receive |
|---|---|---|
| Subjective titration | Active comparator | After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient. Receives: Device: subjective titration |
| DISE-assisted titration | Experimental | Incremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated. Receives: Diagnostic Test: DISE-assisted titration |
| PSG-guided titration | Experimental | An overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced. Receives: Diagnostic Test: PSG-guided titration |
What is being measured
The primary outcome is the main question the study is designed to answer.
The amount of protrusion (mm)
The protrusive position that was predicted as the effective target protrusive position during each titration method (subjective titration, RCMP titration PSG and RCMP titration DISE) will be assessed and compared between the different titration methods.
Measured: After the patient underwent the three titration procedures, so approximately 4 months after start of the study
Secondary outcomes (1)
The apnea/hypopnea index (AHI) derived from the polysomnographic evaluation.
The efficacy of the MAD therapy will be assessed as a measure of treatment outcome by comparingthe baseline AHI with the AHI under MAD therapy.
Measured: After the patient underwent the three titration procedures, so approximately 4 months after start of the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2018
- Study start22 May 2019
- Primary completion7 Apr 2021
- Study completion7 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- More trials run by University Hospital, AntwerpThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomized, crossover study
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Antwerp
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, ethisch.comite@uza.be, University Hospital, Antwerp
- Investigators
- Olivier Vanderveken, MD, PhD, Principal investigator, University Hospital, Antwerp
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03716648
- Sponsor's protocol ID
- 18/33/364
- Status last verified
- Jul 2021
- First submitted
- 9 Oct 2018
- Last updated
- 30 Jul 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Dieltjens M, Braem MJ, Op de Beeck S, Vroegop AVMT, Kazemeini E, Van de Perck E, Beyers J, Kastoer C, Wouters K, Willemen M, Verbraecken JA, Vanderveken OM. Remotely controlled mandibular positioning of oral appliance therapy during polysomnography and drug-induced sleep endoscopy compared with conventional subjective titration in patients with obstructive sleep apnea: protocol for a randomized crossover trial. Trials. 2019 Oct 29;20(1):615. doi: 10.1186/s13063-019-3698-4.
PubMed 31665059
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determination of the Optimal Mandibular Position During Oral Appliance Therapy With a Mandibular Advancement Device in Patients Diagnosed With Obstructive Sleep Apnea.
- ClinicalTrials.gov ID
- NCT03716648
- Acronym / sponsor ID
- 18/33/364
- Conditions
- Obstructive Sleep Apnea
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10 participants (actual)
- Lead sponsor
- University Hospital, AntwerpUniversity, hospital or other
- Study start
- 22 May 2019 (actual)
- Primary completion
- 7 Apr 2021 (actual)
- Study completion
- 7 Apr 2021 (actual)
- First posted
- 23 Oct 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this prospective randomized cross-over trial, 3 different titration procedures will be compared:
- titration of the mandibular advancement device (MAD) in the home setting based on both the physical limits of the patient's mandibular protrusion and the resolution of subjective complaints, as currently often used in routine clinical practice;
- an overnight titration PSG using the remotely controlled mandibular positioner (RCMP) with stepwise mandibular protrusion until respiratory events are reduced and
- incremental protrusion of the mandible during DISE using the RCMP until upper airway collapse at all collapsible levels is eliminated.
The aim of this study is to prospectively compare the target protrusion, as well as the treatment outcome in terms of treatment efficacy, of the 3 different titration protocols.
Detailed description
After inclusion, each patient will undergo three different titration procedures of the protrusive mandibular position or target protrusion for the MAD treatment, in a randomized order: subjective titration, titration during DISE, titration during PSG.
- Subjective titration: After fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient.
- Titration during drug-induced sleep endoscopy (DISE) - DISE-assisted titration: The DISE will be performed by an ear-nose-throat (ENT)surgeon experienced in DISE in order to visualize the dose-dependent effect of the mandibular protrusion on the upper airway collapsibility. The DISE is performed in a semi-dark and silent operating theatre with the patient lying in supine position. The different collapsible levels of the upper airway that can be investigated during DISE are the palate (velopharynx), the oropharynx, the tongue base, the hypopharynx and the epiglottis. The degree of collapse at each level is reported as none, partial or complete. The pattern of the pharyngeal collapse during the obstructive events are classified as concentric, anteroposterior and/or laterolateral. Upon connection of the RCMP to a dedicated laptop, calibration of the actual versus the software-guided protrusion is verified using the RCMP ruler and proprietary developed software, to rule out day-to-day variation caused by environmental factors such as room temperature or humidity. This procedure ensures the mandibular displacement to be read out correctly from the ruler present at the upper tray fitted over the tooth arcs. After the calibration, the RCMP-trays are fitted in edge-to-edge position to avoid excessive muscle tension. A flexible fibreoptic nasendoscope will be introduced by the ENT surgeon in the awake patient to evaluate the awake upper airway state. Thereafter, sedation will be induced by intravenous administration of midazolam (bolus injection of 1.0 to 2.0 mg) and propofol using a target-controlled infusion system (2.0 to 3.0 μg/mL). The transition to unconsciousness similar to stage 2 sleep is aimed at and examined by assuring absence of patients' eyelash reflex after stimulation by means of a gentle brush. Findings are noted using a uniform upper airway scoring system evaluating level of snoring, presence of apneas and degree of oxygen saturation, degree and configuration of obstruction(s) and the level of upper airway collapse. When target sedation is reached, examined by assuring absence of patients' eyelash reflex after stimulation by means of a gentle brush, the RCMP will be remotely protruded in increments of 2 mm in response to the visualized upper airway collapse at the different collapsible levels until a stable upper airway together with absence of desaturations and snoring is reached. If a stable upper airway in absence of snoring is noted, oxygen desaturation and apneas are evaluated, and the mandible will be remotely retruded for 1 mm. If the upper airway remains stable, further so-called 'reversed titration' will continue. This approach will be repeated until the effective target protrusive position can be determined, defined as the minimal mandibular threshold position corresponding to a stable upper airway in the absence of snoring, oxygen desaturation and apneas. When a stable upper airway is reached, the titration procedure will be continued in 0.5 mm steps, to be as precise as possible. After every protrusive or retrusive movement the RCMP protrusion will be checked on the RCMP ruler versus the protrusion measured by the software, assuring correct positioning of the mandible during the upper airway evaluation.
- Titration during polysomnography (PSG):
At the start of the PSG, the participant's dental trays are attached to the mandibular positioner of the RCMP device, and the positioner is calibrated to the PSG system using the device software. The titration procedure that will be used in this study is previously described. Once asleep, the patient's mandible will be protruded remotely in 0.5 mm steps in response to evidence of apneas and/or hypopneas. If an EEG arousal occurs, no further advancement will be attempted until stable sleep resumes. Stepwise mandibular protrusion will continue until respiratory events are reduced to normal in all sleep stages, and in both supine and lateral position, or until maximal protrusion is reached. Afterwards, an independent researcher will score the PSG together with body position and mandibular position signals and will predict success or failure with MAD therapy based on the predetermined interpretative rules. The patient needs to have rapid eye movement (REM) sleep for ≥ 5 minutes in the supine position or in the lateral position, if REM in supine position was not observed. All REM cycles will be evaluated to identify a minimum 5 minutes' interval where ≤ 1 respiratory event occurred. If this is the case, the PSG will be scored as predicted MAD success for that protrusive position. If not, the PSG will be judged to predict therapeutic failure. The predicted effective target protrusive position is the minimum protrusive position that is associated with ≤ 1 respiratory event per 5-minutes REM interval. If the PSG is scored as predicted success, the predicted effective target protrusive position is provided to the dentist to start MAD therapy in that position. If the PSG is scored as predicted failure, an alternative position equal to 75% of maximal protrusion is provided.
A polygraphic evaluation of the MAD efficacy will be planned after each titration procedure. Furthermore, the patients will be asked to fill out questionnaires regarding snoring, daytime sleepiness (Epworth Sleepiness Scale, ESS), fatigue (Checklist Individual Strength, CIS20R) and side effects of the MAD treatment.
A wash-out period of one week is inserted between the polygraphic evaluation of the protrusive position obtained during a titration procedure and the start of the next titration procedure.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Randomized, crossover study
| Arm | Type | Receives |
|---|---|---|
| Subjective titration | Active comparator | Device: subjective titrationAfter fitting the MAD, there is a 1-month period during which the patients get used to wearing the device and titrate the MAD based on improvement of subjective complaints. The actual mechanism of titration will be individually trained with each patient. |
| DISE-assisted titration | Experimental | Diagnostic Test: DISE-assisted titrationIncremental protrusion of the mandible during drug-induced sleep endoscopy using the remotely controlled mandibular positioner until upper airway collapse at all collapsible levels is eliminated. |
| PSG-guided titration | Experimental | Diagnostic Test: PSG-guided titrationAn overnight titration polysomnograph using the remotely controlled mandibular positioner with stepwise mandibular protrusion until respiratory events are reduced. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients with moderate to severe obstructive sleep apnea (OSA) (obstructive AHI (oAHI) ≥ 15/h)
- BMI < 30 kg/m²
- Age > 18 year
- PSG < 2 years old with stable body weight (+/- 5 kg), no ENT surgery since most recent PSG and stable clinical condition
- Normal clinical and radiological (incl. OPG), periodontal en temporomandibular joint examination
Key exclusion criteria (9 listed)
- Edentulous patients
- Insufficient teeth to support the mandibular advancement device
- Active periodontal problems including tooth mobility
- Active temporomandibular joint dysfunction
- Limited maximum protrusive capacity (<6 mm)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DISE-assisted titrationTitration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy. | Diagnostic test | DISE-assisted titration |
| PSG-guided titrationTitration of the mandibular position with the remotely controlled mandibular positioner during drug-induced sleep endoscopy. | Diagnostic test | PSG-guided titration |
| subjective titrationTitration of the mandibular position based on subjective improvement in symptoms like snoring and excessive daytime sleepiness. | Device | Subjective titration |
Primary outcome
The amount of protrusion (mm)
Time frame: After the patient underwent the three titration procedures, so approximately 4 months after start of the study
The protrusive position that was predicted as the effective target protrusive position during each titration method (subjective titration, RCMP titration PSG and RCMP titration DISE) will be assessed and compared between the different titration methods.
1 secondary outcome
The apnea/hypopnea index (AHI) derived from the polysomnographic evaluation.
Time frame: After the patient underwent the three titration procedures, so approximately 4 months after start of the study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2021.
- Derived from this study: PubMed 31665059Dieltjens M, Braem MJ, Op de Beeck S, Vroegop AVMT, Kazemeini E, Van de Perck E, Beyers J, Kastoer C, Wouters K, Willemen M, Verbraecken JA, Vanderveken OM. Remotely controlled mandibular positioning of oral appliance therapy during polysomnography and drug-induced sleep endoscopy compared with conventional subjective titration in patients with obstructive sleep apnea: protocol for a randomized crossover trial. Trials. 2019 Oct 29;20(1):615. doi: 10.1186/s13063-019-3698-4.
- Individual participant dataSharing planned: No
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Olivier Vanderveken, MD, PhD principal investigator
University Hospital, Antwerp
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DISE-assisted titration, PSG-guided titration and subjective titration in people with Obstructive Sleep Apnea, run by University Hospital, Antwerp at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The amount of protrusion (mm) (time frame: After the patient underwent the three titration procedures, so approximately 4 months after start of the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03716648, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2021.